Cellceutix Corporation (CTIX)
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial in Miami, FL. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.
The above link is kept updated.
Ongoing Human Trials: http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
Product Pipeline: http://cellceutix.com/pipeline/
Recent News and Press Releases:
Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
Share Structure: See SEC filing link above for current share structure
Cellceutix IP - Patent Filings:
|Publication number ||US8338454 B2 |
|Publication type ||Grant |
|Application number ||US 12/780,132 |
|Publication date ||Dec 25, 2012 |
|Filing date ||May 14, 2010 |
|Priority date ||May 20, 2009 |
|Also published as ||CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More » |
|Publication number ||12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2 |
|Inventors ||Krishna Menon |
|Original Assignee ||Cellceutix Corporation |
|Export Citation ||BiBTeX, EndNote, RefMan |
|Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42) |
|External Links: USPTO, USPTO Assignment, Espacenet |
Investor Relations: firstname.lastname@example.org
Following is a WEEKLY chart:
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp